GSK PLC (GSK) Business News March 13, 2026, 15:44 UTC GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk Full text
There are no comments here yet...